Shionogi and AnGes MG start phase I of NF-κB decoy oligo A, directed towards atopic dermatitis

In Japan, 2,8 million people suffer from atopic dermatitis, 10 million in the US.

AnGes MG press release, April 17, 2013

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny